Abemaciclib vs Ribociclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
Abemaciclib · Verzenio
Marketed by Eli Lilly
NCT02107703 · Phase 3 · active, not recruiting
This was a randomized, double-blind, placebo-controlled phase 3 trial of 669 women. The primary endpoint, progression-free survival, was met with a clear, statistically significant advantage for abemaciclib plus fulvestrant.
Next expected readout: December 2026 · NCT05305924 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) (met)
Result source: NCT02107703
Ribociclib
Marketed by Novartis
NCT02422615 · Phase 3 · completed
The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.
Next expected readout: November 2026 · NCT02608216 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) (met)
Result source: NCT02422615
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Abemaciclib | Ribociclib |
|---|---|---|
| PFS, median | 16.4 vs 9.3+7.1 vs placeboNCT0210770311 other results
| 20.5 vs 12.8+7.7 vs placeboNCT024226159 other results
|
| OS, median | 45.8 vs 37.3+8.5 vs placeboNCT021077036 other results
| 63.9 vs 51.4+12.5 vs placeboNCT019580211 other result
|
| ORR | 35.2% vs 16.1%+19.1 vs placeboNCT021077034 other results
| 32.4% vs 21.5%+10.9 vs placeboNCT024226156 other results
|
| Clinical benefit rate | 72.2% vs 56.1%+16.1 vs placeboNCT021077038 other results
| 70.2% vs 62.8%+7.4 vs placeboNCT024226154 other results
|
PFS, median
- Abemaciclib
- 16.4 vs 9.3+7.1 vs placeboNCT02107703
11 other results
- 8.3 vs 5.7 NCT02675231
- 5.7 vs 5.7 NCT02675231
- 6.3 vs 1.9 NCT03280563
- 6 NCT02102490
- 2.1 NCT03099174
- 13.6 NCT03099174
- 33.1 NCT03099174
- 2.1 NCT02308020
- 4.4 NCT02308020
- 1.4 NCT02308020
- 1.2 NCT02308020
- Ribociclib
- 20.5 vs 12.8+7.7 vs placeboNCT02422615
9 other results
- 23.8 vs 13 NCT02278120
- 21.8 NCT03096847
- 8.8 NCT03096847
- 16.5 NCT03096847
- 27.6 vs 14.7 NCT03671330
- 5.3 vs 2.8 NCT02632045
- 21.8 vs 12.8 NCT03839823
- 25.1 NCT03822468
- 26.9 NCT03822468
OS, median
- Abemaciclib
- 45.8 vs 37.3+8.5 vs placeboNCT02107703
6 other results
- 26.7 vs 26.0 NCT03280563
- 22.3 NCT02102490
- 10.1 NCT02308020
- 13.4 NCT02308020
- 7.1 NCT02308020
- 2.9 NCT02308020
- Ribociclib
- 63.9 vs 51.4+12.5 vs placeboNCT01958021
1 other result
- 69.2 vs 55.5 NCT03671330
ORR
- Abemaciclib
- 35.2% vs 16.1%+19.1 vs placeboNCT02107703
4 other results
- 26.3% vs 10% NCT03280563
- 19.7% NCT02102490
- 32.9% vs 13.9% NCT02675231
- 13.9% vs 13.9% NCT02675231
- Ribociclib
- 32.4% vs 21.5%+10.9 vs placeboNCT02422615
6 other results
- 40.9% vs 29.7% NCT02278120
- 40.7% vs 27.5% NCT01958021
- 29.3% NCT02941926
- 45.3% NCT03822468
- 41.5% NCT03822468
- 66.1% vs 61.8% NCT03839823
Clinical benefit rate
- Abemaciclib
- 72.2% vs 56.1%+16.1 vs placeboNCT02107703
8 other results
- 58.2% vs 38% NCT02675231
- 45.6% vs 38% NCT02675231
- 42.1% vs 15% NCT03280563
- 42.4% NCT02102490
- 13% NCT02308020
- 26.9% NCT02308020
- 26.1% NCT02308020
- 9.1% NCT02308020
- Ribociclib
- 70.2% vs 62.8%+7.4 vs placeboNCT02422615
4 other results
- 79.1% vs 69.7% NCT02278120
- 79.6% vs 72.8% NCT01958021
- 70.7% NCT02941926
- 81.3% vs 74.5% NCT03839823
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety
Coverage. Abemaciclib: 12 of 12 rows · Ribociclib: 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Abemaciclib Rows use multiple source trials | Ribociclib Rows use multiple source trials |
|---|---|---|
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 42.4% (n=132)a,b,c,d NCT02102490 · Phase 2 4 other source trials13% (n=23) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 26.9% (n=52) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 26.1% (n=23) NCT02308020 · Phase 2 · registry result, not featured evidence 9.1% (n=22) NCT02308020 · Phase 2 · registry result, not featured evidence | 70.7% (n=3246)a,b,c,d NCT02941926 · Phase 3 · combination |
| Duration of Response time to event · months | NA vs 25.6 placebo monthsb,d NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3 other source trials9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 13.36 vs 13.03 Fulvestrant months NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | NA vs NA placebo monthsb,d NCT02422615 · Phase 3 · combination 3 other source trials21.3 vs 17.5 placebo months NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 45.2 vs 17.6 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence 37 vs 17.6 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence |
| Duration of Response time to event · months No placebo or comparator arm | 8.6 monthse,c,d NCT02102490 · Phase 2 4 other source trials11.12 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 17.54 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 5.78 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 4.63 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 28.8 months600 mgf,e,c,d NCT03822468 · Phase 2 · registry result, not featured evidence show 1 more dose26.5 months400 mg NCT03822468 · Phase 2 · registry result, not featured evidence |
| ORR responder rate · % of participants No placebo or comparator arm | 19.7% (n=132)a,b,c,d NCT02102490 · Phase 2 | 29.3% (n=3246)a,b,c,d NCT02941926 · Phase 3 · combination 2 other source trials41.5% (n=188)400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 45.3% (n=188)600 mg NCT03822468 · Phase 2 · registry result, not featured evidence |
| ORR event count · % of participants No placebo or comparator arm | 60.6% (n=33)*1000 mgf,g,h,d NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted show 3 more doses19.4% (n=31)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted 3.8% (n=26)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 6.7% (n=15)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted | 50% (n=2)*g,h,d NCT03477396 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted |
| Overall Survival time to event · months No placebo or comparator arm | 22.32 monthsa,e,c,d NCT02102490 · Phase 2 4 other source trials10.06 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 13.38 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 7.13 months NCT02308020 · Phase 2 · registry result, not featured evidence 2.93 months NCT02308020 · Phase 2 · registry result, not featured evidence | NA monthsf,a,e,c,d NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more dosesNA months NCT03096847 · Phase 3 · registry result, not featured evidence · combination NA months NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 6 monthsa,e,c,d NCT02102490 · Phase 2 8 other source trials2.07 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 4.41 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 1.45 months NCT02308020 · Phase 2 · registry result, not featured evidence 1.22 months NCT02308020 · Phase 2 · registry result, not featured evidence 13.6 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 33.1 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 2.1 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination NA months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 21.8 monthsf,a,e,c,d NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more doses16.5 months NCT03096847 · Phase 3 · registry result, not featured evidence · combination 8.8 months NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| Time to Response time to event · months No placebo or comparator arm | 3.52 months1000 mgf,g,h,c,d NCT03099174 · Phase 1 · registry result, not featured evidence · combination show 3 more doses5.45 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1.94 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 9.36 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 9 months600 mgf,g,h,c,d NCT03822468 · Phase 2 · registry result, not featured evidence show 1 more dose13.1 months400 mg NCT03822468 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 25.6%i NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more results5.3% NCT02102490 · Phase 2 31.7%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 21.2%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 10.1%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.3%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 16.7%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 8.3%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 25%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 34.5%Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 33.3%Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence —Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence 17.4%Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence —Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination 17.5% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | n/a: no completion milestoneRibociclib + Fulvestrantj NCT02422615 · Phase 3 · combination show 27 more results—Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination n/a: no completion milestoneRibociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestoneRibociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 59.9% NCT02941926 · Phase 3 · combination 68.7%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 76.9%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 87.9%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestonePK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePostmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePremenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestone600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence n/a: no completion milestone400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0% NCT03477396 · Phase 2 · registry result, not featured evidence · combination 68.8%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 3.2% NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —i NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more results— NCT02102490 · Phase 2 3.2%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.5%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination —150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence —Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence —Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence —Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 18.2%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 12.9%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 25%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 19.2%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 20%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 10.5%Ribociclib + Fulvestrantj NCT02422615 · Phase 3 · combination show 27 more results—Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination 4.8%Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 11.4%Ribociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 15.5% NCT02941926 · Phase 3 · combination 22.6%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 23.1%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 17.8%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 11.8%PK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence 6.5%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 1.3%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 12.8%600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence 11.2%400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence — NCT03477396 · Phase 2 · registry result, not featured evidence · combination 7.1%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence — NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 29.3%i NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more results25% NCT02102490 · Phase 2 7.9%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 6.6%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 19.5%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 30.8%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 33.3%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 21.7%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 22.2%Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 27.6%Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 33.3%Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence 28.6%Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence 17.4%Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence 41.2%Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination 35.9% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 33.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 51.6%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 37.5%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 50%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 26.7%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | —Ribociclib + Fulvestrantj NCT02422615 · Phase 3 · combination show 27 more results37.1%Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 24.2%Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 25%Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 32.3%Ribociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 — NCT02941926 · Phase 3 · combination 30.4%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination 27.3%Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 19.2%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 28.7%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination —PK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 29.4%PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence 0%PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 27.3%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 0%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 17.7%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 0%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —600 mg NCT03822468 · Phase 2 · registry result, not featured evidence 19.7%600mg NCT03822468 · Phase 2 · registry result, not featured evidence —400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 20.2%400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0% NCT03477396 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 15.2%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 6.7% NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | i diarrhoea 87.1% (placebo 27.8%) neutropenia 49.7% (placebo 3.6%) nausea 49.4% (placebo 24.7%) NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 23 more resultsdiarrhoea 28.6% anaemia 22.2% fatigue 20.6% NCT04707196 · Phase 4 · registry result, not featured evidence · combination diarrhoea 29.9% neutropenia 24.8% anaemia 23.4% NCT04707196 · Phase 4 · registry result, not featured evidence · combination 150 mg + 8 mg/kg diarrhoea 77.9% fatigue 53.2% nausea 41.6% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg + 500 mg diarrhoea 79.5% fatigue 57.7% nausea 48.7% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 200 mg diarrhoea 87.5% nausea 62.5% anaemia 58.3% NCT03703466 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 91.7% nausea 58.3% anaemia 41.7% NCT03703466 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 95.7% anaemia 47.8% nausea 47.8% NCT03703466 · Phase 2 · registry result, not featured evidence diarrhoea 55.6% fatigue 33.3% nausea 33.3% NCT02308020 · Phase 2 · registry result, not featured evidence · combination diarrhoea 77.6% fatigue 48.3% nausea 44.8% NCT02308020 · Phase 2 · registry result, not featured evidence · combination alanine aminotransferase increased 66.7% anaemia 44.4% diarrhoea 44.4% NCT02308020 · Phase 2 · registry result, not featured evidence diarrhoea 53.6% fatigue 39.3% nausea 28.6% NCT02308020 · Phase 2 · registry result, not featured evidence abdominal pain 21.7% diarrhoea 21.7% neutropenia 21.7% NCT02308020 · Phase 2 · registry result, not featured evidence fatigue 52.9% nausea 41.2% diarrhoea 35.3% NCT02308020 · Phase 2 · registry result, not featured evidence · combination diarrhoea 84.6% fatigue 43.6% nausea 43.6% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 1000 mg diarrhoea 100% decreased appetite 66.7% vomiting 66.7% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg anaemia 100% diarrhoea 100% aspartate aminotransferase increased 85.7% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 85.7% asthenia 71.4% neutropenia 71.4% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 90.9% nausea 66.7% neutrophil count decreased 51.5% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 93.5% nausea 67.7% neutrophil count decreased 51.6% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 100% nausea 75% asthenia 62.5% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 61.5% nausea 61.5% decreased appetite 42.3% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 93.3% asthenia 60% headache 53.3% NCT03099174 · Phase 1 · registry result, not featured evidence · combination | j neutropenia 57.8% (placebo 2.5%) nausea 46.8% (placebo 31.1%) diarrhoea 34% (placebo 22.4%) NCT02422615 · Phase 3 · combination show 18 more resultsneutropenia 57.9% (placebo 6.5%) arthralgia 38.8% (placebo 36.2%) neutrophil count decreased 35.5% (placebo 1.5%) NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 nausea 75% (placebo 32.1%) anaemia 50% (placebo 7.3%) diarrhoea 50% (placebo 26.7%) NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 65.3% (placebo 5.5%) nausea 54.8% (placebo 32.1%) fatigue 43.4% (placebo 36.1%) NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 50.8% nausea 40.8% fatigue 38.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 48.1% nausea 42.1% fatigue 40.4% NCT03096847 · Phase 3 · registry result, not featured evidence · combination fatigue 57.7% neutropenia 57.7% hot flush 42.3% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 46.5% nausea 43.3% fatigue 37.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 100% (placebo 23.4%) white blood cell count decreased 100% (placebo 33.8%) anaemia 94.1% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence aspartate aminotransferase increased 12.5% (placebo 40.3%) blood alkaline phosphatase increased 6.3% (placebo 27.3%) blood cholesterol increased 6.3% (placebo 16.9%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 85.7% (placebo 23.4%) white blood cell count decreased 80.5% (placebo 33.8%) anaemia 48.1% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 1.4% (placebo 40.3%) aspartate aminotransferase increased 1.4% (placebo 40.3%) blood bilirubin increased 1.4% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 88.6% (placebo 23.4%) white blood cell count decreased 87.3% (placebo 33.8%) anaemia 55.7% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 2.7% (placebo 23.4%) alanine aminotransferase increased 1.4% (placebo 40.3%) aspartate aminotransferase increased 1.4% (placebo 40.3%) NCT03671330 · Phase 2 · registry result, not featured evidence 600mg neutropenia 66.5% leukopenia 27.7% anaemia 26.1% NCT03822468 · Phase 2 · registry result, not featured evidence 400mg neutropenia 53.2% alanine aminotransferase increased 26.1% aspartate aminotransferase increased 21.8% NCT03822468 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 100% alkaline phosphatase increased 100% aspartate aminotransferase increased 100% NCT03477396 · Phase 2 · registry result, not featured evidence · combination 600 mg neutropenia 65.2% anaemia 35.7% leukopenia 25.9% NCT03839823 · Phase 2 · registry result, not featured evidence neutropenia 71.7% (placebo 15.3%) fatigue 33.3% (placebo 32.2%) aspartate aminotransferase increased 25% (placebo 28.8%) NCT02632045 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation context differs: eligible sex differs (FEMALE versus ALL).
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for both studies.
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gTrial phases differ: Phase 1 versus Phase 2.
- hPopulation context differs: registered conditions differ.
- iPopulation comparability has not been reviewed for 23 of these studies.
- jPopulation comparability has not been reviewed for 24 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Abemaciclib
show 2 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 19 further endpoints in the CSV export.
Ribociclib
show 4 more results
+ 38 further endpoints in the CSV export.
Breast Cancer
Shared mechanism: CDK4 and CDK6 · full Breast Cancer pipeline
Abemaciclib · Verzenio
Marketed by Eli Lilly
NCT02107703 · Phase 3 · active, not recruiting
This was a randomized, double-blind, placebo-controlled phase 3 trial of 669 women. The primary endpoint, progression-free survival, was met with a clear, statistically significant advantage for abemaciclib plus fulvestrant.
Next expected readout: December 2026 · NCT05305924 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4) (met)
Result source: NCT02107703
Ribociclib
Marketed by Novartis
NCT02422615 · Phase 3 · completed
The study randomly assigned 726 participants to ribociclib plus fulvestrant or placebo plus fulvestrant and was quadruple-blinded for the primary comparison. Its radiographically assessed progression-free survival endpoint was significantly better with ribociclib; participants were later unblinded and offered crossover after a protocol amendment.
Next expected readout: November 2026 · NCT02608216 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3) (met)
Result source: NCT02422615
Results for Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Abemaciclib: 16 of 16 rows · Ribociclib: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Abemaciclib Rows use multiple source trials | Ribociclib Rows use multiple source trials |
|---|---|---|
| Clinical Benefit responder rate · % of participants | 72.2% (n=446) vs 56.1% (n=223) placeboa,b NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3 other source trials45.6% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 58.2% (n=79) vs 38% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 42.1% (n=38) vs 15% (n=20) Fulvestrant NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | 70.2% (n=484) vs 62.8% (n=242) placeboa,b NCT02422615 · Phase 3 · combination 3 other source trials79.1% (n=335) vs 69.7% (n=337) placebo NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 79.6% (n=334) vs 72.8% (n=334) placebo NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 81.3% (n=112) vs 74.5% (n=110) Combination Chemotherapy600 mg NCT03839823 · Phase 2 · registry result, not featured evidence |
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 42.4% (n=132)c,a,d,b NCT02102490 · Phase 2 4 other source trials13% (n=23) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 26.9% (n=52) NCT02308020 · Phase 2 · registry result, not featured evidence · combination 26.1% (n=23) NCT02308020 · Phase 2 · registry result, not featured evidence 9.1% (n=22) NCT02308020 · Phase 2 · registry result, not featured evidence | 70.7% (n=3246)c,a,d,b NCT02941926 · Phase 3 · combination |
| Duration of Response time to event · months | NA vs 25.6 placebo monthsa,b NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3 other source trials9.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5 vs NA Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 13.36 vs 13.03 Fulvestrant months NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | NA vs NA placebo monthsa,b NCT02422615 · Phase 3 · combination 3 other source trials21.3 vs 17.5 placebo months NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 45.2 vs 17.6 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence 37 vs 17.6 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence |
| Duration of Response time to event · months No placebo or comparator arm | 8.6 monthse,d,b NCT02102490 · Phase 2 4 other source trials11.12 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 17.54 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 5.78 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 4.63 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 28.8 months600 mgf,e,d,b NCT03822468 · Phase 2 · registry result, not featured evidence show 1 more dose26.5 months400 mg NCT03822468 · Phase 2 · registry result, not featured evidence |
| ORR responder rate · % of participants | 35.2% (n=446) vs 16.1% (n=223) placeboa,b NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3 other source trials13.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 32.9% (n=79) vs 13.9% (n=79) Trastuzumab + Standard of Care Chemotherapy150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 26.3% (n=38) vs 10% (n=20) Fulvestrant NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | 32.4% (n=484) vs 21.5% (n=242) placeboa,b NCT02422615 · Phase 3 · combination 3 other source trials40.9% (n=335) vs 29.7% (n=337) placebo NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 40.7% (n=334) vs 27.5% (n=334) placebo NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 66.1% (n=112) vs 61.8% (n=110) Combination Chemotherapy600 mg NCT03839823 · Phase 2 · registry result, not featured evidence |
| ORR responder rate · % of participants No placebo or comparator arm | 19.7% (n=132)c,a,d,b NCT02102490 · Phase 2 2 other source trials53.6% (n=224) NCT02441946 · Phase 2 · registry result, not featured evidence · combination 46.4% (n=224) NCT02441946 · Phase 2 · registry result, not featured evidence · combination | 29.3% (n=3246)c,a,d,b NCT02941926 · Phase 3 · combination 3 other source trials41.5% (n=188)400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 45.3% (n=188)600 mg NCT03822468 · Phase 2 · registry result, not featured evidence 16.7% (n=12) NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination |
| ORR event count · % of participants No placebo or comparator arm | 60.6% (n=33)*1000 mgf,g,h,b NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 20 Participants as posted show 3 more doses19.4% (n=31)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted 3.8% (n=26)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 6.7% (n=15)*1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted | 50% (n=2)*g,h,b NCT03477396 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted |
| Overall Survival time to event · months | 45.8 vs 37.25 placebo monthsa,b NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 1 other source trial26.71 vs 26.02 Fulvestrant months NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | NA vs 40 placebo monthsa,b NCT02422615 · Phase 3 · combination 5 other source trialsNA vs 40.9 placebo months NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 63.9 vs 51.4 placebo months NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 NA vs 55.5 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence 69.2 vs 55.5 placebo months NCT03671330 · Phase 2 · registry result, not featured evidence NA vs NA Combination Chemotherapy months600 mg NCT03839823 · Phase 2 · registry result, not featured evidence |
| Overall Survival time to event · months No placebo or comparator arm | 22.32 monthsc,e,d,b NCT02102490 · Phase 2 4 other source trials10.06 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 13.38 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 7.13 months NCT02308020 · Phase 2 · registry result, not featured evidence 2.93 months NCT02308020 · Phase 2 · registry result, not featured evidence | NA monthsf,c,e,d,b NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more dosesNA months NCT03096847 · Phase 3 · registry result, not featured evidence · combination NA months NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| PFS time to event · months | 16.4 vs 9.3 placebo monthsa,b NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3 other source trials5.7 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 8.3 vs 5.7 Trastuzumab + Standard of Care Chemotherapy months150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.28 vs 1.95 Fulvestrant months NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination | 20.5 vs 12.8 placebo monthsf,a,b NCT02422615 · Phase 3 · combination show 1 more doseNA vs 10.9 placebo months NCT02422615 · Phase 3 · combination |
| PFS time to event · months No placebo or comparator arm | 6 monthsc,e,d,b NCT02102490 · Phase 2 8 other source trials2.07 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 4.41 months NCT02308020 · Phase 2 · registry result, not featured evidence · combination 1.45 months NCT02308020 · Phase 2 · registry result, not featured evidence 1.22 months NCT02308020 · Phase 2 · registry result, not featured evidence 13.6 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 33.1 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 2.1 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination NA months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 21.8 monthsf,c,e,d,b NCT03096847 · Phase 3 · registry result, not featured evidence · combination show 2 more doses16.5 months NCT03096847 · Phase 3 · registry result, not featured evidence · combination 8.8 months NCT03096847 · Phase 3 · registry result, not featured evidence · combination |
| Time to Response time to event · months No placebo or comparator arm | 3.52 months1000 mgf,g,h,d,b NCT03099174 · Phase 1 · registry result, not featured evidence · combination show 3 more doses5.45 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1.94 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 9.36 months1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 9 months600 mgf,g,h,d,b NCT03822468 · Phase 2 · registry result, not featured evidence show 1 more dose13.1 months400 mg NCT03822468 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 25.6%i NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 28 more results5.3% NCT02102490 · Phase 2 31.7%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 21.2%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 10.1%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 6.3%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 16.7%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 8.3%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 25%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 34.5%Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 33.3%Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence —Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence 17.4%Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence —Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination 6.6%Abemaciclib NCT02441946 · Phase 2 · registry result, not featured evidence 2.7%Abemaciclib + Anastrozole NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib + Anastrozole Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib + Anastrozole Cycle 2 NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence 17.5% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | n/a: no completion milestoneRibociclib + Fulvestrantj NCT02422615 · Phase 3 · combination show 34 more results—Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination 59.9% NCT02941926 · Phase 3 · combination n/a: no completion milestoneRibociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestoneRibociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 68.7%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 76.9%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 87.9%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestonePK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePostmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePremenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence n/a: no completion milestone600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence n/a: no completion milestone400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0% NCT03477396 · Phase 2 · registry result, not featured evidence · combination 68.8%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 3.2% NCT02632045 · Phase 2 · registry result, not featured evidence · combination 50% NCT03078751 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —500 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —400 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —300 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 7.7%Cohort B: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —Cohort C: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —i NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 28 more results— NCT02102490 · Phase 2 3.2%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 1.5%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination —150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —200 mg NCT03703466 · Phase 2 · registry result, not featured evidence —Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence —Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence —Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence —Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination 1.3%Abemaciclib NCT02441946 · Phase 2 · registry result, not featured evidence 1.4%Abemaciclib + Anastrozole NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib + Anastrozole Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib + Anastrozole Cycle 2 NCT02441946 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 18.2%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 12.9%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 25%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 19.2%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 20%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | 10.5%Ribociclib + Fulvestrantj NCT02422615 · Phase 3 · combination show 34 more results—Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination 15.5% NCT02941926 · Phase 3 · combination 4.8%Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 11.4%Ribociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 22.6%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination —Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 23.1%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 17.8%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 11.8%PK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence —PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence 6.5%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 1.3%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 12.8%600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence 11.2%400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence — NCT03477396 · Phase 2 · registry result, not featured evidence · combination 7.1%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence — NCT02632045 · Phase 2 · registry result, not featured evidence · combination 15.4% NCT03078751 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —500 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —400 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —300 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —Cohort B: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —Cohort C: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 29.3%i NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 28 more results25% NCT02102490 · Phase 2 7.9%Abemaciclib + Fulvestrant NCT04707196 · Phase 4 · registry result, not featured evidence · combination 6.6%Abemaciclib + NSAI NCT04707196 · Phase 4 · registry result, not featured evidence · combination 19.5%150 mg + 8 mg/kg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 30.8%150 mg + 8 mg/kg + 500 mg NCT02675231 · Phase 2 · registry result, not featured evidence · combination 12.5%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 33.3%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 21.7%200 mg NCT03703466 · Phase 2 · registry result, not featured evidence 22.2%Part A Abemaciclib: HR+, HER2+ Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 27.6%Part B Abemaciclib: HR+, HER2- Bre NCT02308020 · Phase 2 · registry result, not featured evidence · combination 33.3%Part C Abemaciclib: Surgical Resec NCT02308020 · Phase 2 · registry result, not featured evidence 28.6%Part D Abemaciclib: NSCLC NCT02308020 · Phase 2 · registry result, not featured evidence 17.4%Part E Abemaciclib: Melanoma NCT02308020 · Phase 2 · registry result, not featured evidence 41.2%Part F: Abemaciclib HR+ Breast Can NCT02308020 · Phase 2 · registry result, not featured evidence · combination —Abemaciclib NCT02441946 · Phase 2 · registry result, not featured evidence —Abemaciclib + Anastrozole NCT02441946 · Phase 2 · registry result, not featured evidence · combination 1.4%Abemaciclib + Anastrozole Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence · combination 7.4%Abemaciclib + Anastrozole Cycle 2 NCT02441946 · Phase 2 · registry result, not featured evidence · combination 1.3%Abemaciclib Cycle 1 NCT02441946 · Phase 2 · registry result, not featured evidence 35.9% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 0%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 33.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 51.6%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 37.5%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 50%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 26.7%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination | —Ribociclib + Fulvestrantj NCT02422615 · Phase 3 · combination show 34 more results37.1%Ribociclib + Fulvestrant (On-treat NCT02422615 · Phase 3 · combination — NCT02941926 · Phase 3 · combination —Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 24.2%Ribociclib + NSAI/Tamoxifen + Gose NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 25%Crossover to Ribociclib + Letrozol NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 32.3%Ribociclib + Letrozole NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 30.4%Ribociclib + Letrozole Cohort A NCT03096847 · Phase 3 · registry result, not featured evidence · combination 27.3%Ribociclib + Letrozole Cohort B NCT03096847 · Phase 3 · registry result, not featured evidence · combination 19.2%Ribociclib + Letrozole Cohort B1 NCT03096847 · Phase 3 · registry result, not featured evidence · combination 28.7%Ribociclib + Letrozole Cohort B2 NCT03096847 · Phase 3 · registry result, not featured evidence · combination —PK Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 29.4%PK Cohort - Ribociclib (On-treatme NCT03671330 · Phase 2 · registry result, not featured evidence 0%PK Cohort - Ribociclib (Post-treat NCT03671330 · Phase 2 · registry result, not featured evidence —Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 27.3%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 0%Postmenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 17.7%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence 0%Premenopausal Cohort - Ribociclib NCT03671330 · Phase 2 · registry result, not featured evidence —600 mg NCT03822468 · Phase 2 · registry result, not featured evidence 19.7%600mg NCT03822468 · Phase 2 · registry result, not featured evidence —400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 20.2%400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0% NCT03477396 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 15.2%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 6.7% NCT02632045 · Phase 2 · registry result, not featured evidence · combination 15.4% NCT03078751 · Phase 2 · registry result, not featured evidence · combination 100%600 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 100%500 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 100%400 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 100%300 mg NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 83.3%Cohort B: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination —Cohort C: Ribociclib + Trastuzumab NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | i diarrhoea 87.1% (placebo 27.8%) neutropenia 49.7% (placebo 3.6%) nausea 49.4% (placebo 24.7%) NCT02107703 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 26 more resultsdiarrhoea 28.6% anaemia 22.2% fatigue 20.6% NCT04707196 · Phase 4 · registry result, not featured evidence · combination diarrhoea 29.9% neutropenia 24.8% anaemia 23.4% NCT04707196 · Phase 4 · registry result, not featured evidence · combination 150 mg + 8 mg/kg diarrhoea 77.9% fatigue 53.2% nausea 41.6% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 150 mg + 8 mg/kg + 500 mg diarrhoea 79.5% fatigue 57.7% nausea 48.7% NCT02675231 · Phase 2 · registry result, not featured evidence · combination 200 mg diarrhoea 87.5% nausea 62.5% anaemia 58.3% NCT03703466 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 91.7% nausea 58.3% anaemia 41.7% NCT03703466 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 95.7% anaemia 47.8% nausea 47.8% NCT03703466 · Phase 2 · registry result, not featured evidence diarrhoea 55.6% fatigue 33.3% nausea 33.3% NCT02308020 · Phase 2 · registry result, not featured evidence · combination diarrhoea 77.6% fatigue 48.3% nausea 44.8% NCT02308020 · Phase 2 · registry result, not featured evidence · combination alanine aminotransferase increased 66.7% anaemia 44.4% diarrhoea 44.4% NCT02308020 · Phase 2 · registry result, not featured evidence diarrhoea 53.6% fatigue 39.3% nausea 28.6% NCT02308020 · Phase 2 · registry result, not featured evidence abdominal pain 21.7% diarrhoea 21.7% neutropenia 21.7% NCT02308020 · Phase 2 · registry result, not featured evidence fatigue 52.9% nausea 41.2% diarrhoea 35.3% NCT02308020 · Phase 2 · registry result, not featured evidence · combination diarrhoea 41.9% constipation 36.5% fatigue 25.7% NCT02441946 · Phase 2 · registry result, not featured evidence · combination diarrhoea 46.5% nausea 30.9% fatigue 28.6% NCT02441946 · Phase 2 · registry result, not featured evidence · combination diarrhoea 38.7% constipation 34.7% fatigue 22.7% NCT02441946 · Phase 2 · registry result, not featured evidence diarrhoea 84.6% fatigue 43.6% nausea 43.6% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 1000 mg diarrhoea 100% decreased appetite 66.7% vomiting 66.7% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg anaemia 100% diarrhoea 100% aspartate aminotransferase increased 85.7% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 85.7% asthenia 71.4% neutropenia 71.4% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 90.9% nausea 66.7% neutrophil count decreased 51.5% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 93.5% nausea 67.7% neutrophil count decreased 51.6% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 100% nausea 75% asthenia 62.5% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 61.5% nausea 61.5% decreased appetite 42.3% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 1000 mg diarrhoea 93.3% asthenia 60% headache 53.3% NCT03099174 · Phase 1 · registry result, not featured evidence · combination | j neutropenia 57.8% (placebo 2.5%) nausea 46.8% (placebo 31.1%) diarrhoea 34% (placebo 22.4%) NCT02422615 · Phase 3 · combination show 24 more resultsneutropenia 57.9% (placebo 6.5%) arthralgia 38.8% (placebo 36.2%) neutrophil count decreased 35.5% (placebo 1.5%) NCT02278120 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 nausea 75% (placebo 32.1%) anaemia 50% (placebo 7.3%) diarrhoea 50% (placebo 26.7%) NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 65.3% (placebo 5.5%) nausea 54.8% (placebo 32.1%) fatigue 43.4% (placebo 36.1%) NCT01958021 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 50.8% nausea 40.8% fatigue 38.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 48.1% nausea 42.1% fatigue 40.4% NCT03096847 · Phase 3 · registry result, not featured evidence · combination fatigue 57.7% neutropenia 57.7% hot flush 42.3% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutropenia 46.5% nausea 43.3% fatigue 37.6% NCT03096847 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 100% (placebo 23.4%) white blood cell count decreased 100% (placebo 33.8%) anaemia 94.1% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence aspartate aminotransferase increased 12.5% (placebo 40.3%) blood alkaline phosphatase increased 6.3% (placebo 27.3%) blood cholesterol increased 6.3% (placebo 16.9%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 85.7% (placebo 23.4%) white blood cell count decreased 80.5% (placebo 33.8%) anaemia 48.1% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 1.4% (placebo 40.3%) aspartate aminotransferase increased 1.4% (placebo 40.3%) blood bilirubin increased 1.4% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 88.6% (placebo 23.4%) white blood cell count decreased 87.3% (placebo 33.8%) anaemia 55.7% (placebo 13%) NCT03671330 · Phase 2 · registry result, not featured evidence neutrophil count decreased 2.7% (placebo 23.4%) alanine aminotransferase increased 1.4% (placebo 40.3%) aspartate aminotransferase increased 1.4% (placebo 40.3%) NCT03671330 · Phase 2 · registry result, not featured evidence 600mg neutropenia 66.5% leukopenia 27.7% anaemia 26.1% NCT03822468 · Phase 2 · registry result, not featured evidence 400mg neutropenia 53.2% alanine aminotransferase increased 26.1% aspartate aminotransferase increased 21.8% NCT03822468 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 100% alkaline phosphatase increased 100% aspartate aminotransferase increased 100% NCT03477396 · Phase 2 · registry result, not featured evidence · combination 600 mg neutropenia 65.2% anaemia 35.7% leukopenia 25.9% NCT03839823 · Phase 2 · registry result, not featured evidence neutropenia 71.7% (placebo 15.3%) fatigue 33.3% (placebo 32.2%) aspartate aminotransferase increased 25% (placebo 28.8%) NCT02632045 · Phase 2 · registry result, not featured evidence · combination neutropenia 53.8% (placebo 0%) fatigue 46.2% (placebo 4.2%) nausea 46.2% (placebo 25%) NCT03078751 · Phase 2 · registry result, not featured evidence · combination 600 mg neutrophil count decreased 100% platelet count decreased 100% anemia 66.7% NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 500 mg neutrophil count decreased 100% platelet count decreased 100% anemia 66.7% NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 400 mg anemia 100% platelet count decreased 100% white blood cell decreased 100% NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination 300 mg anemia 100% platelet count decreased 100% white blood cell decreased 100% NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination anemia 83.3% diarrhea 41.7% nausea 41.7% NCT02657343 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation context differs: eligible sex differs (FEMALE versus ALL).
- bThe assessment timepoint is not available for both results.
- cTrial phases differ: Phase 2 versus Phase 3.
- dTreatment context has not been resolved for both arms.
- ePopulation comparability has not been reviewed for both studies.
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gTrial phases differ: Phase 1 versus Phase 2.
- hPopulation context differs: registered conditions differ.
- iPopulation comparability has not been reviewed for 28 of these studies.
- jPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Abemaciclib
show 2 more results
show 4 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 34 further endpoints in the CSV export.
Ribociclib
show 4 more results
+ 41 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abemaciclib's landscape · Ribociclib's landscape